Dual-target gene therapy in Parkinson’s disease: a multicenter phase 1 trial
Nature Medicine - Phase 1 results reveal that BBM-P002, a dual-target gene therapy co-delivering TH and DDC, is safe and well tolerated in Parkinson’s disease, with 12-month motor...
nature.com